3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC external medicine for treating hair loss; and SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides Remitch, a nalfuraphine hydrochloride orally disintegrating tablets; MN709, a minoxidil foam formulation for the treatment of androgenetic alopecia and alopecia areata; and other products in the areas of nephrology, hematology, oncology, auto-immune, ophthalmology, and dermatology and metabolism. Further, it engages in trading; research and development of biotechnology and drugs; sells chemical products; and retail of pharmaceuticals. Additionally, the company provides project management and consultation, technology, sports, financial, clinic, investment advisory, and agricultural services, as well as manufactures medical devices. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
